Heart-on-a-chip mimics drug response seen in humans

Researchers from TARA Biosystems, Inc. and GlaxoSmithKline (GSK) today published data demonstrating that TARA’s engineered heart-on-a-chip system replicated drug responses found in adult humans. The findings, published in the journal Toxicological Sciences, show TARA’s 3-D-cardiac tissue platform can predict how human hearts will respond to a wide range of drugs, something that has been a challenge in pre-clinical models until […]

Continue reading »

Team develops test to predict immunotherapy response in kidney cancer

A novel imaging test shows promise for identifying kidney cancer patients most likely to benefit from immunotherapy. In a study published today in the Journal for ImmunoTherapy of Cancer, investigators with the UT Southwestern Medical Center Kidney Cancer Program developed a new test to illuminate kidney cancers that may respond to checkpoint inhibitors. The strategy involved transforming an immunotherapy drug, […]

Continue reading »

Japanese study finds concerning trends in cervical cancer and treatment response

Cervical cancer rates can be greatly reduced through preventive measures against the human papillomavirus (HPV) along with proactive cancer screening. Japan may be showing how ignoring that knowledge could prove hazardous, as it is the only advanced economy in which the cervical cancer rate is increasing. New research adds further nuance to this situation. Researchers centered at Osaka University examined […]

Continue reading »

Major response to immunotherapy in early-stage mismatch repair deficient colon cancer

Pre-operative treatment with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab achieves major pathological responses in 100 percent of early-stage colon cancers with mismatch repair deficiencies, according to results reported at ESMO 2018 from the first exploratory phase II trial to investigate this approach. Restoring patients’ immune response against cancer cells with checkpoint inhibitors is an established treatment […]

Continue reading »

Duvelisib has marked response, survival benefit in difficult-to-treat leukemia and lymphoma

For some patients with difficult-to-treat leukemia and lymphoma, the investigational oral medicine duvelisib may significantly improve disease outcomes, according to phase III trial data published today in the journal Blood. The DUO trial studied the head-to-head comparison of duvelisib versus ofatumumab, an approved standard-of-care chemotherapy for relapsed or treatment-resistant chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). According to […]

Continue reading »

Scientists engineer way to prevent immune response to gene therapy in mice

Stanford University School of Medicine researchers have demonstrated that gene therapy can be effective without causing a dangerous side effect common to all gene therapy: an autoimmune reaction to the normal protein, which the patient’s immune system is encountering for the first time. The researchers showed this in a mouse model that accurately recapitulates Duchenne muscular dystrophy. One in every […]

Continue reading »

Human microbiome influences rotavirus vaccine response

In a proof-of-concept study in healthy adult men, scientists in the Netherlands found that microbiome manipulation with antibiotics influenced the response to oral rotavirus vaccine. Specifically, they found higher levels of viral shedding in those receiving antibiotic treatment prior to vaccination compared with controls receiving no antibiotic treatment prior to vaccination. The study is a human demonstration that altering the […]

Continue reading »
1 2